MP01-04 LONG-TERM GROSS HEMATURIA IMPROVEMENTS AFTER PROSTATIC ARTERY EMBOLIZATION: COMPARING RESULTS IN GLAND VOLUMES OF ≤80 ML VERSUS >80 ML

Abstract

You have accessJournal of UrologyCME1 May 2022MP01-04 LONG-TERM GROSS HEMATURIA IMPROVEMENTS AFTER PROSTATIC ARTERY EMBOLIZATION: COMPARING RESULTS IN GLAND VOLUMES OF ≤80 ML VERSUS >80 ML Saumik Rahman, Taylor Powell, Lawrence Staib, and Raj Ayyagari Saumik RahmanSaumik Rahman More articles by this author , Taylor PowellTaylor Powell More articles by this author , Lawrence StaibLawrence Staib More articles by this author , and Raj AyyagariRaj Ayyagari More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002513.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To compare long-term results for gross hematuria improvement in ≤80 mL versus >80 mL prostate gland volume (PGV) cohorts treated with spherical particle prostatic artery embolization (PAE). METHODS: 106 patients with prostate-related gross episodic hematuria (EH) or severe hematuria (SH) (requiring admission and bladder irrigation) who underwent technically successful PAE with spherical particles from December 2013 through September 2021 were retrospectively reviewed. Patients with active urine infection, urinary calculi, or urological cancers were not included. Patients were divided into cohorts of PGV ≤80 mL or >80 mL and followed at 1, 3, 6, 12, 24, 36, and 48 months after PAE. Pre- and post-PAE blood transfusions and hematuria-related healthcare visits were tabulated. RESULTS: 17 patients had PGV ≤80 mL (mean=60 mL±11 mL, age=76.3±9.2 y, Charlson comorbidity index (CCI)=4.4±2.2); all had EH only. 89 patients had PGV >80 mL (mean=189 mL±107 mL, age=73.0±8.5 y, CCI=3.9±1.8); 73 of these presented with EH and 16 with SH. After PAE, both ≤80 mL and >80 mL cohorts had dramatic reduction in gross hematuria, sustained through 48 months. Both cohorts had similar treatment success and had similar proportions of patients with clear urine, residual/recurrent EH, or residual/recurrent SH throughout (table). For all patients, 41 units of blood were transfused prior to PAE and 3 units transfused after, all within 48 hours of PAE in 2 patients. There were 36 healthcare visits for hematuria prior to PAE, with 7 post-PAE hematuria-related visits as of latest follow-up (mean=1130±631 days). No relationships between post-PAE transfusions or hematuria-related visits and PGV were observed. CONCLUSIONS: Severe hematuria only presented in patients with PGV >80 mL. Improvements in prostate-related EH and SH after PAE were substantial and sustained through 4 years, with similar trends observed in both ≤80 mL and >80 mL patient cohorts. PAE is an effective treatment for prostate-related gross hematuria, regardless of gland size. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e2 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Saumik Rahman More articles by this author Taylor Powell More articles by this author Lawrence Staib More articles by this author Raj Ayyagari More articles by this author Expand All Advertisement PDF DownloadLoading ...